T1	p 23 29	asthma
T2	p 33 39	adults
T3	p 230 285	31 adult asthmatic patients in a double-blind crossover
T4	i 46 87	sodium cromoglycate pressurized aerosol :
T5	i 122 212	Sodium cromoglycate formulated as a pressurized aerosol ( 2 mg 4-times daily ) and placebo
T6	i 311 330	Sodium cromoglycate
T7	i 347 354	placebo
T8	i 769 790	sodium cromoglycate .
T9	i 811 880	bronchodilators ( theophylline and aerosol beta-stimulants combined )
T10	i 933 952	sodium cromoglycate
T11	i 975 982	placebo
T12	i 1053 1105	sodium cromoglycate delivered by pressurized aerosol
T13	i 1136 1143	placebo
T14	o 358 392	improving breathlessness at rest (
T15	o 415 443	breathlessness on exertion (
T16	o 471 489	quality of sleep (
T17	o 538 579	morning peak expiratory flow rate value (
T18	o 619 620	'
T19	o 650 662	clinicians '
T20	o 988 1000	side-effects
T21	o 1168 1186	asthmatic symptoms
T22	o 1214 1220	amount